This Health Affairs blog post provides background on U.S. drug prices and summarizes an expert roundtable discussion held in June 2020 about the relationship between drug prices and innovation. The roundtable was convened by the USC-Brookings Schaeffer Initiative for Health Policy, with support from the Commonwealth Fund, and included current and former pharmaceutical and biotech executives, physician/scientist entrepreneurs, private equity and venture capitalists, and economists. Read more here.
You are here: / / Balancing Lower U.S. Prescription Drug Prices And Innovation